Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medartis Holding AGXSWX:MED -0.11%80 Cash-to-Debt is 0.13 as of Jun. 2026, which is 88% below its 10-year median of 1.05. GuruFocus rates XSWX:MED with a GF Score™ of 80/100 and a GF Value™ of CHF107.06 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Medartis Holding AG ranks worse than 88.95% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Medartis Holding AG's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.13.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Medartis Holding AGcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Medartis Holding AG's Cash-to-Debt or its related term are showing as below:
XSWX:MED'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03 Med: 1.05 Max: 34.42
Current: 0.13
During the past 12 years, Medartis Holding AG's highest Cash to Debt Ratio was 34.42. The lowest was 0.03. And the median was 1.05.
XSWX:MED's Cash-to-Debt is ranked worse than 88.95% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.61
vs XSWX:MED: 0.13
Medartis Holding AG (XSWX:MED) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Medartis Holding AG Cash-to-Debt Related Terms
Medartis Holding AG Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Medartis Holding AG's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XSWX:MED vs ABT, SYK, MDT: Cash-to-Debt Comparison
For the Medical Devices subindustry, Medartis Holding AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medartis Holding AG Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medartis Holding AG's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Medartis Holding AG's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medartis Holding AG (XSWX:MED) has a Cash-to-Debt of 0.13 as of Jun. 2026. This is 88% below median its historical median of 1.05. Over the past decade, Medartis Holding AG's Cash-to-Debt has ranged from 0.03 to 34.42. According to the industry distribution chart, Medartis Holding AG ranks #749 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 89%.
Is Medartis Holding AG's Cash-to-Debt too high?
Medartis Holding AG's current Cash-to-Debt of 0.13 is 88% below median its 10-year median of 1.05. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 34.42. The Medical Devices & Instruments industry median Cash-to-Debt is 1.61. Medartis Holding AG's value of 0.13 is 91.9% below this industry median. Based on the distribution chart, Medartis Holding AG ranks #749 out of 842 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medartis Holding AG has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medartis Holding AG's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medartis Holding AG ranks #749 out of 842 companies for Cash-to-Debt. This places Medartis Holding AG in the lower half of its industry. The industry median Cash-to-Debt is 1.61. Medartis Holding AG's value of 0.13 is 91.9% below this benchmark. Historically, Medartis Holding AG's own Cash-to-Debt has ranged from 0.03 to 34.42 over the past decade. While the company's 10-year median is 1.05 vs. the industry median of 1.61, Medartis Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.61, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medartis Holding AG's current Cash-to-Debt of 0.13 is 91.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medartis Holding AG's current Cash-to-Debt is 0.13, which is 88% below median its own 10-year median of 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medartis Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Medartis Holding AG (XSWX:MED) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF107.06, compared to a current price of CHF88.00 — trading 17.8% below its estimated fair value. The current Cash-to-Debt is 0.13, which is 88% below median its 10-year median of 1.05 and 91.9% below the Medical Devices & Instruments industry median of 1.61. Medartis Holding AG's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Medartis Holding AG (XSWX:MED), the current Cash-to-Debt is 0.13 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medartis Holding AG (XSWX:MED) Overvalued in 2026?
Based on GuruFocus' analysis, Medartis Holding AG stock appears to be undervalued.
The current stock price of CHF88.00 is trading 17.8% below its estimated GF Value™ of CHF107.06.
GuruFocus considers Medartis Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:MED:
Cash-to-Debt: 0.13 (88% below median its 10-year median of 1.05)
GF Value™: CHF107.06 vs. price of CHF88.00 (17.8% below fair value)
Industry Position: 91.9% below the Medical Devices & Instruments median (#749 of 842)
No single metric tells the full story. See the XSWX:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for the Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from Europe, Middle East and Africa (EMEA) and also has a presence in North America, Asia Pacific, and Latin America.
80GF Score
Get the complete analysis for XSWX:MED
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MED has been successfully added to your 
